Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 2, 2012, Pages 564-569

  Tawara, Isao ^a   Sun, Yaping ^a   Lewis, Eli C ^b   Toubai, Tomomi ^a   Evers, Rebecca ^a   Nieves, Evelyn ^a   Azam, Tania ^c   Dinarello, Charles A ^c   Reddy, Pavan ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; Interleukin

Indexed keywords

ALPHA 1 ANTITRYPSIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE SEVERITY; EFFECTOR CELL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MONOTHERAPY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; RISK REDUCTION; STEM CELL EXPANSION;

ALPHA 1-ANTITRYPSIN; ANIMALS; BONE MARROW TRANSPLANTATION; CYTOKINES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MICE; MICE, INBRED C57BL; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

ANIMALIA;

EID: 84862908801     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1117665109     Document Type: Article

References (55)

1. Appelbaum FR (2007) Hematopoietic-cell transplantation at 50. N Engl J Med 357: 1472-1475.
2. Welniak LA, Blazar BR, Murphy WJ (2007) Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 25:139-170. (Pubitemid 46697905)
3. Paczesny S, Hanauer D, Sun Y, Reddy P (2010) New perspectives on the biology of acute GVHD. Bone Marrow Transplant 45(1):1-11.
4. Antin JH, Ferrara JL (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964-2968. (Pubitemid 23004498)
5. Riley JL, June CH, Blazar BR (2009) Human T regulatory cell therapy: Take a billion or so and call me in the morning. Immunity 30:656-665.
6. Tawara I, et al. (2010) A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease. J Immunol 185:3866-3872.
7. Taylor PA, Noelle RJ, Blazar BR (2001) CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 193:1311-1318.
8. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S (2002) Donor-type CD4(+) CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 196:389-399. (Pubitemid 34875667)
9. Teshima T, et al. (2002) Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8:575-581. (Pubitemid 34633434)
10. Tawara I, et al. (2011) Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res 17(1):77-88.
11. Abhyankar S, Gilliland DG, Ferrara JL (1993) Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation 56:1518-1523. (Pubitemid 24018815)
12. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J (2003) Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant 9:292-303. (Pubitemid 38351814)
13. Antin JH, et al. (2002) Interleukin-1 blockade does not prevent acute graft-versus-host disease: Results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100:3479-3482.
14. Alousi AM, et al. (2009) Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs. host disease: A randomized phase II trial from the BMT CTN. Blood 114:511-517.
15. Silverman EK, Sandhaus RA (2009) Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 360:2749-2757.
16. Aldonyte R, Jansson L, Ljungberg O, Larsson S, Janciauskiene S (2004) Polymerized alpha-antitrypsin is present on lung vascular endothelium. New insights into the biological significance of alpha-antitrypsin polymerization. Histopathology 45:587-592. (Pubitemid 40029818)
17. Carrell RW (1986) alpha 1-Antitrypsin: Molecular pathology, leukocytes, and tissue damage. J Clin Invest 78:1427-1431.
18. Krivit W, Miller J, Nowicki M, Freier E (1988) Contribution of monocyte-macrophage system to serum alpha 1-antitrypsin. J Lab Clin Med 112:437-442.
19. Shapiro L, Pott GB, Ralston AH (2001) Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB J 15(1):115-122. (Pubitemid 32061662)
20. Kok KF, et al. (2007) Heterozygous alpha-I antitrypsin deficiency as a co-factor in the development of chronic liver disease: A review. Neth J Med 65(1):160-166. (Pubitemid 47161617)
21. Hashemi M, Naderi M, Rashidi H, Ghavami S (2007) Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus. Diabetes Res Clin Pract 75:246-248. (Pubitemid 44894602)
22. Janciauskiene S, et al. (2004) Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin. Biochem Biophys Res Commun 321:592-600. (Pubitemid 39118381)
23. Pott GB, Chan ED, Dinarello CA, Shapiro L (2009) Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol 85:886-895.
24. Janciauskiene SM, Nita IM, Stevens T (2007) Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J Biol Chem 282:8573-8582. (Pubitemid 47093518)
25. Churg A, et al. (2001) Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest 81:1119-1131. (Pubitemid 32772072)
26. Lewis EC, Shapiro L, Bowers OJ, Dinarello CA (2005) Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci USA 102:12153-12158. (Pubitemid 41291144)
27. Lewis EC, et al. (2008) alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci USA 105:16236-16241.
28. Koulmanda M, et al. (2008) Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci USA 105: 16242-16247.
29. Zhang B, et al. (2007) Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes 56:1316-1323.
30. Huang H, et al. (2004) Alpha1-antitrypsin inhibits angiogenesis and tumor growth. Int J Cancer 112:1042-1048. (Pubitemid 39507012)
31. Jie Z, et al. (2003) Protective effects of alpha 1-antitrypsin on acute lung injury in rabbits induced by endotoxin. Chin Med J (Engl) 116:1678-1682. (Pubitemid 38008236)
32. Toldo S, et al. (2011) Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol 51:244-251.
33. Reddy P, Negrin R, Hill GR (2008) Mouse models of bone marrow transplantation. Biol Blood Marrow Transplant 14(1, Suppl 1):129-135. (Pubitemid 350286851)
34. Hill GR, et al. (1997) Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 90:3204-3213. (Pubitemid 27444217)
35. Reddy P, et al. (2001) Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 194:1433-1440. (Pubitemid 33081518)
36. Reddy P, et al. (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 101:3921-3926. (Pubitemid 38381078)
37. Hill GR, et al. (1999) Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 104:459-467. (Pubitemid 29534330)
38. Sykes M (2001) Mixed chimerism and transplant tolerance. Immunity 14:417-424.
39. Shlomchik WD, et al. (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285:412-415. (Pubitemid 29343964)
40. Zeiser R, et al. (2008) Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 111:453-462.
41. Strom TB (2005) Saving islets from allograft rejection. Proc Natl Acad Sci USA 102: 12651-12652.
42. Bettelli E, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-238.
43. Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: Endogenous activators of dendritic cells. Nat Med 5:1249-1255. (Pubitemid 29535601)
44. Arora PK, Miller HC, Aronson LD (1978) alpha1-Antitrypsin is an effector of immunological stasis. Nature 274:589-590.
45. Münch J, et al. (2007) Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129:263-275. (Pubitemid 46574967)
46. Kalis M, Kumar R, Janciauskiene S, Salehi A, Cilio CM (2010) α 1-antitrypsin enhances insulin secretion and prevents cytokine-mediated apoptosis in pancreatic β-cells. Islets 2(3):185-189.
47. Shin HJ, et al. (2011) Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 118:2342-2350.
48. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA (2009) Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 21:281-285.
49. Marcondes AM, et al. (2011) Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood 118(18):5031-5039.
50. Subramaniyam D, et al. (2010) Cholesterol rich lipid raft microdomains are gateway for acute phase protein, SERPINA1. Int J Biochem Cell Biol 42:1562-1570.
51. Subramaniyam D, et al. (2010) Effects of alpha 1-antitrypsin on endotoxin-induced lung inflammation in vivo. Inflamm Res 59:571-578.
52. Aldonyte R, Jansson L, Janciauskiene S (2004) Concentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitro. BMC Cell Biol 5(5):11.
53. Zhou X, Shapiro L, Fellingham G,Willardson BM, Burton GF (2011) HIV replication in CD4+ T lymphocytes in the presence and absence of follicular dendritic cells: Inhibition of replication mediated by α-1-antitrypsin through altered IκBα ubiquitination. J Immunol 186:3148-3155.
54. Papadopoulou A, Lloyd DR, Williams MD, Darbyshire PJ, Booth IW (1996) Gastrointestinal and nutritional sequelae of bone marrow transplantation. Arch Dis Child 75: 208-213. (Pubitemid 26313265)
55. Paczesny S, et al. (2009) A biomarker panel for acute graft-versus-host disease. Blood 113:273-278.